<?xml version="1.0" encoding="UTF-8" ?>
<!DOCTYPE Articles SYSTEM "HBI_DTD">


<journal>
<language>en</language>
<journal_id_issn>1726-7536</journal_id_issn>
<journal_id_issn_online>1735-8507</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi></journal_id_doi>
<journal_id_isnet></journal_id_isnet>
<journal_id_iranmedex>69</journal_id_iranmedex>
<journal_id_magiran>2139</journal_id_magiran>
<journal_id_sid>288</journal_id_sid>
<pubdate PubStatus="epublish">
	<type>gregorian</type>
	<year>2015</year>
	<month>8</month>
	<day>25</day>
</pubdate>
<volume>16</volume>
<number>4</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>

<article>
	<language>en</language>
	<article_id_issn></article_id_issn>
	<article_id_issn_online></article_id_issn_online>
	<article_id_pubmed>27110518</article_id_pubmed>
	<article_id_pii></article_id_pii>
	<article_id_doi></article_id_doi>
	<article_id_iranmedex></article_id_iranmedex>
	<article_id_magiran></article_id_magiran>
	<article_id_sid></article_id_sid>
	<title_fa></title_fa>
	<title>HbA&lt;sub&gt;1c&lt;/sub&gt; in Patients with Polycystic Ovary Syndrome: A Potential Marker of Inflammation</title>
	<subject_fa></subject_fa>
	<subject></subject>
	<content_type_fa></content_type_fa>
	<content_type></content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;p&gt;Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that is associated with increased inflammation, insulin resistance, and elevated risk of metabolic complications. hs-CRP is the most reliable marker of inflammation in PCOS patients. When hs-CRP is elevated, it can indicate increased risk of cardiovascular disease. The purpose of the study was to determine if a certain value of HbA&lt;sub&gt;1c&lt;/sub&gt; in PCOS patients should alert clinicians to increased inflammation (as defined by hs-CRP &amp;gt;2 &lt;em&gt;mg/l&lt;/em&gt;), thus potentially be indicative of increased risk of cardiovascular disease.&lt;br /&gt;
Methods: A cohort study was conducted on female patients between the ages of 20 to 45 years who fulfilled the National Institute of Health criteria for PCOS. De-identified data of 46 patients with PCOS were obtained. All clinical tests were conducted after a 12 &lt;em&gt;hr&lt;/em&gt; overnight fast. hs-CRP was measured by latex-enhanced immunonephelometry. Logistic regression analysis was conducted to assess the association between hs-CRP and HbA&lt;sub&gt;1c&lt;/sub&gt;.&lt;br /&gt;
Results: When various HbA&lt;sub&gt;1c&lt;/sub&gt; levels were considered, a cutoff of 5.3% correctly classified patients with hs-CRP &amp;gt;2 &lt;em&gt;mg/l&lt;/em&gt; at 80.4%. Sensitivity was 83.3% and specificity was 75%.&lt;br /&gt;
Conclusion: An HbA&lt;sub&gt;1c&lt;/sub&gt; cut off of 5.3% may be appropriate to initiate efforts for early detection of increased inflammation as a potential sign of risk for cardiovascular disease.&lt;/p&gt;
</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Cardiovasculer disease, HbA1c, hs-CRP, Inflammation, Polycystic ovary syndrome</keyword>
	<start_page>203</start_page>
	<end_page>207</end_page>
	<web_url>https://www.jri.ir/article/646</web_url>
	<pdf_url>https://www.jri.ir/documents/fullpaper/en/646.pdf</pdf_url>
	<author_list><author><first_name>Rami</first_name><middle_name></middle_name><last_name>Mortada</last_name><suffix></suffix><affiliation>Department of Internal Medicine, School of Medicine-Wichita, University of Kansas, Wichita, Kansas, USA</affiliation><first_name_fa></first_name_fa><middle_name_fa></middle_name_fa><last_name_fa></last_name_fa><suffix_fa></suffix_fa><email></email><code>1483</code><coreauthor></coreauthor><affiliation_fa></affiliation_fa></author><author><first_name>Ken</first_name><middle_name></middle_name><last_name>Kallail</last_name><suffix></suffix><affiliation>Department of Internal Medicine, School of Medicine-Wichita, University of Kansas, Wichita, Kansas, USA</affiliation><first_name_fa></first_name_fa><middle_name_fa></middle_name_fa><last_name_fa></last_name_fa><suffix_fa></suffix_fa><email>kkallail@kumc.edu</email><code>1484</code><coreauthor></coreauthor><affiliation_fa></affiliation_fa></author><author><first_name>Frank</first_name><middle_name></middle_name><last_name>Dong</last_name><suffix></suffix><affiliation>Department of Preventive Medicine and Public Health, School of Medicine-Wichita, University of Kansas, Wichita, Kansas, USA</affiliation><first_name_fa></first_name_fa><middle_name_fa></middle_name_fa><last_name_fa></last_name_fa><suffix_fa></suffix_fa><email></email><code>1485</code><coreauthor></coreauthor><affiliation_fa></affiliation_fa></author><author><first_name>Sidika</first_name><middle_name></middle_name><last_name>Karakas</last_name><suffix></suffix><affiliation>Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, University of California-Davis, Sacramento, USA</affiliation><first_name_fa></first_name_fa><middle_name_fa></middle_name_fa><last_name_fa></last_name_fa><suffix_fa></suffix_fa><email></email><code>1486</code><coreauthor></coreauthor><affiliation_fa></affiliation_fa></author></author_list>
</article>

</articleset>
</journal>

